What is it about?
The revolutionary next-generation sequencing technologies provide an unprecedented capacity for whole-genome sequencing, whole-exome sequencing and RNA sequencing-based transcriptome analysis.
Featured Image
Why is it important?
The advent of next-generation sequencing technologies has so dramatically changed biomedical research within the last 6 years, that we can discuss whether it is now the time to translate these genome-wide mapping technologies into clinical use.
Perspectives
The emerging NGS-based biomedical and clinical research now has two major fascinating goals. First, to optimize therapeutic approaches by tailoring combinations of available chemotherapeutics and targeted drugs in responder WGS/WES and transcriptome mapping-based individual selected patients. Second, in a more distant future to develop novel drugs based on a combination of an individual patient’s cancer genome with respect to both his/her structural mutation landscape and the deregulation of functional signaling transduction interaction networks and biological circuits.
Dr Demosthenes E. Ziogas
Peripheral General Hospital of Ioannina - Xatzikosta
Read the Original
This page is a summary of: Targeted therapy: overcoming drug resistance with clinical cancer genome, Expert Review of Anticancer Therapy, July 2012, Taylor & Francis,
DOI: 10.1586/era.12.68.
You can read the full text:
Contributors
The following have contributed to this page
